
Inhalable Drugs Market by Product (Aerosol, Dry Powder Formulation, Spray), Application (Non-Respiratory Diseases, Respiratory Diseases) - Global Forecast 2024-2030
Description
Inhalable Drugs Market by Product (Aerosol, Dry Powder Formulation, Spray), Application (Non-Respiratory Diseases, Respiratory Diseases) - Global Forecast 2024-2030
The Inhalable Drugs Market size was estimated at USD 35.01 billion in 2023 and expected to reach USD 37.60 billion in 2024, at a CAGR 6.05% to reach USD 52.84 billion by 2030.
Global Inhalable Drugs Market
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Inhalable Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Inhalable Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Inhalable Drugs Market, highlighting leading vendors and their innovative profiles. These include Aptargroup, Inc., AstraZeneca PLC, Avalyn Pharma, Inc., Boehringer Ingelheim International GmbH, Cipla Inc., GEA Group Aktiengesellschaft, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer Inc., PureIMS B.V., Respira Therapeutics Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Inhalable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
Product
Aerosol
Dry Powder Formulation
Spray
Application
Non-Respiratory Diseases
Respiratory Diseases
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Inhalable Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Inhalable Drugs Market?
3. What are the technology trends and regulatory frameworks in the Inhalable Drugs Market?
4. What is the market share of the leading vendors in the Inhalable Drugs Market?
5. Which modes and strategic moves are suitable for entering the Inhalable Drugs Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Inhalable Drugs Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidence of respiratory diseases such as chronic obstructive pulmonary diseases and asthma
- 5.1.1.2. Increasing healthcare infrastructure and rising awareness among patients
- 5.1.1.3. Surge in the number of non-respiratory diseases such as Parkinson’s disease
- 5.1.2. Restraints
- 5.1.2.1. Strict regulations for the approval of inhalable drugs
- 5.1.3. Opportunities
- 5.1.3.1. Surge in development of inhalable drugs for ease of administration
- 5.1.3.2. Emerging reformulation of current non-inhaled molecules into inhaled molecules for improved drug delivery
- 5.1.4. Challenges
- 5.1.4.1. Availability of unregulated and alternate therapy
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Inhalable Drugs Market, by Product
- 6.1. Introduction
- 6.2. Aerosol
- 6.3. Dry Powder Formulation
- 6.4. Spray
- 7. Inhalable Drugs Market, by Application
- 7.1. Introduction
- 7.2. Non-Respiratory Diseases
- 7.3. Respiratory Diseases
- 8. Americas Inhalable Drugs Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
- 9. Asia-Pacific Inhalable Drugs Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.
- 10. South Korea
- 9.
- 11. Taiwan
- 9.
- 12. Thailand
- 9.
- 13. Vietnam
- 10. Europe, Middle East & Africa Inhalable Drugs Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.
- 10. Nigeria
- 10.
- 11. Norway
- 10.
- 12. Poland
- 10.
- 13. Qatar
- 10.
- 14. Russia
- 10.
- 15. Saudi Arabia
- 10.
- 16. South Africa
- 10.
- 17. Spain
- 10.
- 18. Sweden
- 10.
- 19. Switzerland
- 10.
- 20. Turkey
- 10.
- 21. United Arab Emirates
- 10.
- 22. United Kingdom
- 11. Competitive Landscape
- 11.1. FPNV Positioning Matrix
- 11.2. Market Share Analysis, By Key Player
- 11.3. Competitive Scenario Analysis, By Key Player
- 12. Competitive Portfolio
- 12.1. Key Company Profiles
- 12.1.1. Aptargroup, Inc.
- 12.1.2. AstraZeneca PLC
- 12.1.3. Avalyn Pharma, Inc.
- 12.1.4. Boehringer Ingelheim International GmbH
- 12.1.5. Cipla Inc.
- 12.1.6. GEA Group Aktiengesellschaft
- 12.1.7. Merck & Co., Inc.
- 12.1.8. Novartis AG
- 12.1.9. Orion Corporation
- 12.1.
- 10. Pfizer Inc.
- 12.1.
- 11. PureIMS B.V.
- 12.1.
- 12. Respira Therapeutics Inc.
- 12.1.
- 13. Sanofi S.A.
- 12.1.
- 14. Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd.
- 12.1.
- 15. Teva Pharmaceutical Industries Ltd.
- 12.2. Key Product Portfolio
- 13. Appendix
- 13.1. Discussion Guide
- 13.2. License & Pricing
- FIGURE 1. INHALABLE DRUGS MARKET RESEARCH PROCESS
- FIGURE 2. INHALABLE DRUGS MARKET SIZE, 2023 VS 2030
- FIGURE 3. INHALABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. INHALABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. INHALABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. INHALABLE DRUGS MARKET DYNAMICS
- FIGURE 7. INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
- FIGURE 8. INHALABLE DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 10. INHALABLE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. AMERICAS INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 12. AMERICAS INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 14. UNITED STATES INHALABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 16. ASIA-PACIFIC INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INHALABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. INHALABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 20. INHALABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.